Laboratorios Farmaceuticos Rovi stock analysis
Laboratorios Farmaceuticos Rovi (0ILL) Share Price & Analysis
0ILL Stock Chart & Stats
- Day’s Range
- EUR 68.45 - EUR 69.80
- 52-Week Range
- EUR 52.45 - EUR 87.50
- Previous Close
- EUR 68.60
- Volume
- N/A
- Average Volume (3M)
- 10.40K
- Market Cap
- EUR 3.51B
- Enterprise Value
- EUR 3.06B
- Total Cash (Recent Filing)
- EUR 128.07M
- Total Debt (Recent Filing)
- EUR 107.69M
- Price to Earnings (P/E)
- 19.2
- Beta
- 1.09
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jul 13, 2026
- Dividend Yield
- 1.12%
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
The debt-free balance sheet and sizable equity base reduce financial risk and give ROVI flexibility to fund capacity, product development, or acquisitions internally. This resilience can help the company absorb operating volatility while preserving strategic options through the next several quarters.
CDMO Expansion
Rapid CDMO growth strengthens ROVI’s second earnings engine and increases the contribution from third-party manufacturing relationships. Phoenix and restored Madrid capacity expand the industrial footprint, while the business benefits from recurring production demand and greater utilization over time.
Okedi Product Momentum
Okedi’s strong sales growth and broader European uptake provide a durable proprietary-product growth driver beyond ROVI’s established portfolio. Continued market penetration can improve product mix and support recurring revenue growth as commercialization expands across additional markets.
Bears Say
Underlying Profit Decline
The reported profit increase was heavily supported by a nonrecurring bargain-purchase gain, while underlying EBITDA and EBIT declined. This indicates that current operating earnings are weaker than headline net profit suggests and places greater importance on execution and recovery in core profitability.
Heparin Franchise Pressure
Heparin remains a large revenue contributor but is experiencing year-on-year erosion, including declines in both LMWH and enoxaparin biosimilar sales. Even with recent bemiparin recovery, continued franchise pressure could weigh on consolidated growth and offset gains from newer products.
Rising Operating Costs
Rapid increases in SG&A and development spending are creating near-term pressure on operating leverage, particularly while underlying EBIT is declining. These investments may support future growth, but they raise the execution burden and could keep margins below recent levels until revenues scale.
Laboratorios Farmaceuticos Rovi News
0ILL FAQ
What was Laboratorios Farmaceuticos Rovi’s price range in the past 12 months?
What is Laboratorios Farmaceuticos Rovi’s market cap?
When is Laboratorios Farmaceuticos Rovi’s upcoming earnings report date?
How were Laboratorios Farmaceuticos Rovi’s earnings last quarter?
Is Laboratorios Farmaceuticos Rovi overvalued?
Does Laboratorios Farmaceuticos Rovi pay dividends?
What is Laboratorios Farmaceuticos Rovi’s EPS estimate?
How many shares outstanding does Laboratorios Farmaceuticos Rovi have?
What happened to Laboratorios Farmaceuticos Rovi’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Laboratorios Farmaceuticos Rovi?
What is the TipRanks Smart Score and how is it calculated?
Laboratorios Farmaceuticos Rovi Stock Smart Score
Company Description
Laboratorios Farmaceuticos Rovi
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The company also markets certain products under license from other manufacturers. Its primary pharmaceutical portfolio includes Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins for preventing and treating venous thromboembolic conditions. Neparvis targets symptomatic chronic heart failure with reduced ejection in adult patients. For managing hypercholesterolemia, Rovi offers Absorcol, Vytorin, and Orvatez. Respiratory diseases like chronic obstructive pulmonary disease are treated with long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is available for men with benign prostatic hyperplasia (BPH) experiencing moderate to severe storage and voiding symptoms who have not adequately responded to monotherapy. Additionally, Medikinet and Medicebrán are used for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Beyond pharmaceuticals, Rovi provides various hospital solutions for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventions, Multihance and Prohance for MRI, and Sonovue for ultrasounds. It also supplies contrast injection systems such as EmpowerCTA+, EmpowerMR, and CT Exprès, along with compatible disposable materials. The company's offerings extend to over-the-counter pharmaceuticals and contract manufacturing services for other firms, producing a range of dosage forms like prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi serves a broad client base, including pharmaceutical wholesalers, medical professionals, nurses, pharmacists, and individual patients. Notably, Rovi has partnered with Moderna, Inc. for the production of an mRNA COVID-19 vaccine candidate. Established in 1946, the company is headquartered in Madrid, Spain, and operates as a subsidiary of Norbel Inversiones, S.L.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Juan Lopez-Belmonte Encina
- Employees
- 2,232
- Website
- www.rovi.es
- Address
- Calle José Isbert, 2, Pozuelo de Alarcón, 28223, ES
Laboratorios Farmaceuticos Rovi (0ILL) Earnings & Revenues
0ILL Earnings Call
Earnings Call SentimentNeutral
The call presented a mix of strong operational and financial positives (double‑digit revenue growth, 38% CDMO growth, improved gross margins, strong cash generation, strategic Phoenix acquisition and clinical progress) alongside material caveats: much of the headline profit uplift was driven by a one‑off EUR 62.4 million badwill, underlying EBITDA and EBIT declined year‑on‑year, SG&A and R&D rose sharply, and the heparin franchise still faces year‑on‑year declines despite recent Q2 improvement. Management maintained cautious full‑year guidance and flagged regulatory and contract timing risks. Overall the results show meaningful momentum in CDMO, cash flow and product development, but underlying operational profitability and cost pressures temper the outlook.
View all GB:0ILL earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |
